Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 19:14:1268119.
doi: 10.3389/fphar.2023.1268119. eCollection 2023.

Redefining the polypill: pros and cons in cardiovascular precision medicine

Siddharth Birla  1 , Arshia Angural  2 , Arya Madathumchalil #  2 , Ritika V Shende #  2 , Sharvani V Shastry #  2 , Manjappa Mahadevappa  3 , Sunil Kumar Shambhu  3 , Prashant Vishwanath  1 , Akila Prashant  1   2
Affiliations
Review

Redefining the polypill: pros and cons in cardiovascular precision medicine

Siddharth Birla et al. Front Pharmacol. .

Abstract

Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hypertension and hyperlipidemia. These contain blood-pressure lowering agents, statins, and anti-platelet agents usually in a fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, as these are proven to increase patients' adherence to medication and improve clinical outcomes. Over the previous years, randomized clinical trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use in primary disease prevention. Here, we have reviewed the concept of polypills, the evidence-based strengths, the limitations of this polypharmacy intervention strategy, and discussed future directions for their use in the primary and secondary preventive management of cardiovascular diseases and associated risk factors.

Keywords: CVD; LDL; NAFLD; genomics; hypertension; multi-drug; polypill; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Aguiar C., Araujo F., Rubio-Mercade G., Carcedo D., Paz S., Castellano J. M., et al. (2022). Cost-effectiveness of the CNIC-polypill strategy compared with separate monocomponents in secondary prevention of cardiovascular and cerebrovascular disease in Portugal: The MERCURY study. J. Health Econ. Outcomes Res. 9 (2), 134–146. 10.36469/001c.39768 - DOI - PMC - PubMed
    1. Alexander D. C., Bundy D. G., Shore A. D., Morlock L., Hicks R. W., Miller M. R. (2009). Cardiovascular medication errors in children. Pediatrics 124 (1), 324–332. 10.1542/peds.2008-2073 - DOI - PubMed
    1. Becerra V., Gracia A., Desai K., Abogunrin S., Brand S., Chapman R., et al. (2015). Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open 5 (5), e007111. 10.1136/bmjopen-2014-007111 - DOI - PMC - PubMed
    1. Bosch J. J., O’donnell M. J., Gao P., Joseph P., Pais P., Xavier D., et al. (2023). Effects of a polypill, aspirin, and the combination of both on cognitive and functional outcomes: A randomized clinical trial. JAMA Neurol. 80 (3), 251–259. 10.1001/jamaneurol.2022.5088 - DOI - PMC - PubMed
    1. Brainin M., Teuschl Y., Martins S. (2022). Polypill: Benefits seen for stroke and other outcomes. Stroke 53, 2695–2701. 10.1161/STROKEAHA.122.037313 - DOI - PubMed